Category: Zacks Small Cap Research

1383940414250400 / 500 POSTS
By David Bautz, PhDNASDAQ:ARLZBusiness UpdateContinued Growth in Zontivity®Aralez (NASDAQ:ARLZ) launched Zontivity® in June 2017 and is now promoting the drug with the company’s 75 person sales force to approximately 12,000 cardiologists, primary car ...
By David Bautz, PhDNASDAQ:OPNTBusiness UpdateOpioid Crisis Continues to WorsenA new report from the Centers for Disease Control (CDC) shows that emergency department visits for opioid overdoses rose 30% in the U.S. from July 2016 to September 2017. T ...
By David Bautz, PhDNASDAQ:VKTXBusiness UpdateViking Therapeutics, Inc. (NASDAQ:VKTX) is a biopharmaceutical company developing treatments for metabolic and endocrine disorders. The company’s lead compounds include: VK5211, which is being developed fo ...
OTC: HSSHFIntroduced in 2009, Bitcoin was the first decentralized digital currency. One Bitcoin was worth roughly $0.003 in early 2010, according to Coinmarketcap.com data. By September of 2017, the Bitcoin / dollar exchange rate had climbed to over ...
By David Bautz, PhDNASDAQ:MTPBusiness UpdateSet to Initiate Clinical Trial of MTX110 in DIPGOn January 16, 2018, Midatech Pharma Plc (NASDAQ:MTP) announced that the U.S. Food and Drug Administration (FDA) approved the investigational new drug (IND) a ...
By Brian Marckx, CFANYSE:VNRXVolitionRx (NYSE:VNRX) reported Q4 results and provided a business update.  Relative to the financials, results continue to come in well within our expectations with Q4 operating expenses and EPS coming in at $4.2M and ($ ...
By Brian Marckx, CFAOTC:SMLRSemler (OTC:SMLR) reported financial results for their fourth quarter and full year ending December 31st.  Results were, again, extraordinarily strong, including revenue which set another new record high, beating the prio ...
By John Vandermosten, CFA NASDAQ:RXIIINITIATING COVERAGEWe are initiating coverage of RXi Pharmaceuticals Corp (NASDAQ:RXII) with a $20.00 price target based on our estimates for a 2023 launch of RXI-109 and a 2022 launch of Samcyprone, both thro ...
By David Bautz, PhDTSX:ATE.VData from Phase 2 GI Safety Study Expected Week of Mar. 19, 2018On February 26, 2018, Antibe Therapeutics Inc. (TSX:ATE.V) provided an update on the Phase 2 gastrointestinal (GI) safety study of its lead drug, ATB-346. The ...
By Steven Ralston, CFATSX:WML.VExecutive Summary• Current development effort – drilling campaign • Drilling program at the Laguna Verde Project, which commenced in early December 2017, is in the closing stages  • After the conclusion of th ...
1383940414250400 / 500 POSTS